Emily Cox-Martin1, Lisa H Trahan2,3, Matthew G Cox4, Patrick M Dougherty5, Emily A Lai6, Diane M Novy5. 1. Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 12801 E 17th Ave, Aurora, CO, 80045, USA. Emily.Cox-Martin@ucdenver.edu. 2. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Unit 1330, Houston, TX, 77030, USA. 3. Cedar Creek Associates, LLC, 631 Mill St., Ste. 101, San Marcos, TX, 78666, USA. 4. Adult and Child Consortium for Health Outcomes Research and Delivery Science, School of Medicine, University of Colorado Anschutz Medical Campus, 13199 E. Montview Blvd, Suite 358, Aurora, CO, 80045, USA. 5. Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 409, Houston, TX, 77030, USA. 6. McGovern Medical School, University of Texas, 1885 El Paseo St, # 35303, Houston, TX, 77054, USA.
Abstract
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) and obesity are prevalent in cancer survivors and decrease quality of life; however, the impact of the co-occurrence of these conditions has garnered little attention. This study investigated differences between obese and non-obese cancer survivors with CIPN and predictors of symptom burden and pain. METHODS: Patients with CIPN were administered the MD Anderson Symptom Inventory and a modified version of pain descriptors from the McGill Pain Inventory. Independent t tests assessed group differences between obese and non-obese survivors, and linear regression analyses explored predictors of patient outcomes. RESULTS: Results indicated a significant difference in symptom severity scores for obese (M = 32.89, SD = 25.53) versus non-obese (M = 19.35, SD = 16.08) patients (t(37.86) = -2.49, p = .02). Significant differences were also found for a total number of pain descriptors endorsed by obese (M = 4.21, SD = 3.45) versus non-obese (M = 2.42, SD = 2.69) participants (t(74) = -2.53, p = .01). Obesity was a significant predictor of symptom severity and total pain descriptors endorsed. Other significant predictors included age and months since treatment. CONCLUSIONS: Cancer survivors with CIPN and co-occurring obesity may be more at risk for decreased quality of life through increased symptom severity and pain compared to non-obese survivors. This paper identified risk factors, including obesity, age, and months since treatment, that can be clinically identified for monitoring distress in CIPN patients. Future research should focus on the longitudinal relationship between obesity and CIPN, and robust interventions to address the multifaceted issues faced by cancer survivors.
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) and obesity are prevalent in cancer survivors and decrease quality of life; however, the impact of the co-occurrence of these conditions has garnered little attention. This study investigated differences between obese and non-obese cancer survivors with CIPN and predictors of symptom burden and pain. METHODS:Patients with CIPN were administered the MD Anderson Symptom Inventory and a modified version of pain descriptors from the McGill Pain Inventory. Independent t tests assessed group differences between obese and non-obese survivors, and linear regression analyses explored predictors of patient outcomes. RESULTS: Results indicated a significant difference in symptom severity scores for obese (M = 32.89, SD = 25.53) versus non-obese (M = 19.35, SD = 16.08) patients (t(37.86) = -2.49, p = .02). Significant differences were also found for a total number of pain descriptors endorsed by obese (M = 4.21, SD = 3.45) versus non-obese (M = 2.42, SD = 2.69) participants (t(74) = -2.53, p = .01). Obesity was a significant predictor of symptom severity and total pain descriptors endorsed. Other significant predictors included age and months since treatment. CONCLUSIONS:Cancer survivors with CIPN and co-occurring obesity may be more at risk for decreased quality of life through increased symptom severity and pain compared to non-obese survivors. This paper identified risk factors, including obesity, age, and months since treatment, that can be clinically identified for monitoring distress in CIPN patients. Future research should focus on the longitudinal relationship between obesity and CIPN, and robust interventions to address the multifaceted issues faced by cancer survivors.
Entities:
Keywords:
Cancer; Chemotherapy-induced peripheral neuropathy; Obesity; Pain; Quality of life
Authors: Ping Yang; Andrea L Cheville; Jason A Wampfler; Yolanda I Garces; Aminah Jatoi; Matthew M Clark; Stephen D Cassivi; David E Midthun; Randolph S Marks; Marie-Christine Aubry; Scott H Okuno; Brent A Williams; Francis C Nichols; Victor F Trastek; Hiroshi Sugimura; Linda Sarna; Mark S Allen; Claude Deschamps; Jeff A Sloan Journal: J Thorac Oncol Date: 2012-01 Impact factor: 15.609
Authors: Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse Journal: Support Care Cancer Date: 2014-05-01 Impact factor: 3.603
Authors: Kathleen A Griffith; Ingemar S J Merkies; Elizabeth E Hill; David R Cornblath Journal: J Peripher Nerv Syst Date: 2010-12 Impact factor: 3.494
Authors: Laura Q Rogers; Kerry S Courneya; Philip M Anton; Patricia Hopkins-Price; Steven Verhulst; Sandra K Vicari; Randall S Robbs; Robert Mocharnuk; Edward McAuley Journal: Breast Cancer Res Treat Date: 2014-11-23 Impact factor: 4.872
Authors: Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Alexandre Chan; Daniel L Hertz; Manuel Morales; Elizabeth J Adams; Sharon Gordon; Chia Jie Tan; Nathan P Staff; Jayesh Kamath; Jeong Oh; Shivani Shinde; Doreen Pon; Niharkia Dixit; James D'Olimpio; Cristina Dumitrescu; Margherita Gobbo; Kord Kober; Samantha Mayo; Linda Pang; Ishwaria Subbiah; Andreas S Beutler; Katherine B Peters; Charles Loprinzi; Maryam B Lustberg Journal: Support Care Cancer Date: 2019-07-30 Impact factor: 3.603
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Kathleen A Griffith; Shijun Zhu; Meg Johantgen; Michael D Kessler; Cynthia Renn; Andreas S Beutler; Rahul Kanwar; Nicholas Ambulos; Guido Cavaletti; Jordi Bruna; Chiara Briani; Andreas A Argyriou; Haralabos P Kalofonos; Laura M Yerges-Armstrong; Susan G Dorsey Journal: J Pain Symptom Manage Date: 2017-07-23 Impact factor: 3.612
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Henry Schulz Journal: Oncol Res Treat Date: 2021-10-13 Impact factor: 2.825
Authors: Iva Petrovchich; Kord M Kober; Laura Wagner; Steven M Paul; Gary Abrams; Margaret A Chesney; Kimberly Topp; Betty Smoot; Mark Schumacher; Yvette P Conley; Marilyn Hammer; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-04-30 Impact factor: 5.576
Authors: Sevilay Tümkaya Yılmaz; Anneleen Malfliet; Ömer Elma; Tom Deliens; Jo Nijs; Peter Clarys; An De Groef; Iris Coppieters Journal: J Clin Med Date: 2022-01-27 Impact factor: 4.241
Authors: Araba A Adjei; Camden L Lopez; Daniel J Schaid; Jeff A Sloan; Jennifer G Le-Rademacher; Charles L Loprinzi; Aaron D Norman; Janet E Olson; Fergus J Couch; Andreas S Beutler; Celine M Vachon; Kathryn J Ruddy Journal: Cancers (Basel) Date: 2021-03-03 Impact factor: 6.639